Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 386 plus cisplatin + capecitabine versus placebo plus cisplatin + capecitabine in metastatic gastric or esophageal adenocarcinoma
2007-003573-50Phase 2Completed
- Sponsor
- Amgen
- Start
- Oct 2007
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of trebananib in gastric adenocarcinoma, Esophago-Gastric Adenocarcinoma and esophageal adenocarcinoma (EAC) (3 arms), sponsored by Amgen. Primary endpoints: Progression-free survival and Safety and tolerability. Started Oct 2007; status: completed.
02
Drugs
trebananib
03
Conditions
gastric adenocarcinomaEsophago-Gastric Adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2007-003573-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003573-50.